Holen Sie sich die Stockscreener-App
97.99
2.09%
2.01
Handel nachbörslich:
97.87
-0.12
-0.12%
Schlusskurs vom Vortag:
$95.98
Offen:
$96.64
24-Stunden-Volumen:
2.32M
Relative Volume:
0.70
Marktkapitalisierung:
$18.94B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-26.77
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
+1.53%
1M Leistung:
-17.41%
6M Leistung:
+182.39%
1J Leistung:
+136.41%
1-Tages-Spanne:
$93.79
$98.41
1-Wochen-Bereich:
$93.79
$99.58
52-Wochen-Spanne:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
97.99 | 18.55B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
How Revolution Medicines Inc. stock reacts to Fed rate cutsJuly 2025 Macro Moves & Real-Time Volume Analysis - mfd.ru
Stock Traders Purchase High Volume of Put Options on Revolution Medicines (NASDAQ:RVMD) - MarketBeat
Can Revolution Medicines Inc. Equity Warrant stock reach $100 price targetJuly 2025 Action & Accurate Intraday Trade Tips - mfd.ru
Revolution Medicines, Inc. $RVMD Shares Bought by Candriam S.C.A. - MarketBeat
Layoff Watch: Is Revolution Medicines Inc Equity Warrant subject to activist investor interestMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Update Report: Will Revolution Medicines Inc outperform during market rallies - baoquankhu1.vn
Market Review: Is Revolution Medicines Inc a defensive stockExit Point & Fast Moving Stock Trade Plans - baoquankhu1.vn
Revolution Medicines, Inc. $RVMD Shares Acquired by New York State Common Retirement Fund - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Revolution Medicines jumps on report AbbVie nears takeover - MSN
Earnings Recap: Is Revolution Medicines Inc affected by consumer sentimentJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
(RVMD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - The Manila Times
Revolution Medicines (RVMD) Price Target Increased by 24.66% to 115.71 - Nasdaq
Revolution Medicines (BIT:1RVMD) Price Target Increased by 30.97% to 100.64 - Nasdaq
Bearish Sentiment Observed in Revolution Medicines (RVMD) - GuruFocus
Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine - PharmTech.com
Revolution Medicines plummets on report Merck walks from acquisition talks - MSN
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate - FinancialContent
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $122.00 - MarketBeat
Revolution Medicines (RVMD) Gets Price Target Boost from JP Morg - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Evaluating the 19.27% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Knights of Columbus Asset Advisors LLC Takes $587,000 Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Why Revolution Medicines stock plummeted by almost 17% today - MSN
Revolution Medicines stock stares at big dip after Merck reportedly shelves buyout — but analyst flags opportunity - MSN
Merck is said to halt acquisition talks with cancer drug developer Revolution - MSN
Market Outlook: Is now the right time to enter Revolution Medicines IncWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Merck Ends Revolution Talks As Oncology Focus And Valuation Take Center Stage - Sahm
RVMD stock tumbles as MRK reportedly withdraws buyout offer - MSN
Revolution Medicines shares slide after Merck reportedly walks away from takeover talks - MSN
What is Revolution Medicines Inc.’s market positionWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Revolution Medicines (RVMD) Initiates First Human Trial for RMC-5127 - GuruFocus
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor - GlobeNewswire
48,000 RAS G12V cancer cases a year as Revolution Medicines trials new drug - Stock Titan
Y Intercept Hong Kong Ltd Has $2.58 Million Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Revolution Medicines (RVMD) and Bausch Health Companies (BHC) - The Globe and Mail
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed - Yahoo Finance
Oppenheimer Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer - Yahoo Finance
Truist Financial Initiates Revolution Medicines(RVMD.US) With Buy Rating - 富途牛牛
Oppenheimer Raises Price Target for Revolution Medicines (RVMD) - GuruFocus
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan - Insider Monkey
10 Big Names Stumbling Hard - Insider Monkey
Revolution Medicines Shares Plunge 17% After Merck Acquisition Talks Stall - Intellectia AI
Why Revolution Medicines Stock Plummeted by Almost 17% Today - Finviz
Why Revolution Medicines Stock Plummeted by Almost 17% Today - The Motley Fool
Revolution’s shares dip with report of Merck walking away: Deals Report - biocentury.com
Merck stock slips after report says MRK stepped back from Revolution Medicines talks - TechStock²
MSD Reportedly Ends Takeover Talks with Revolution Medicines - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Shares Gap DownTime to Sell? - MarketBeat
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):